Literature DB >> 3146262

Antibodies to soluble CD4 in HIV-1-infected individuals.

C Thiriart1, J Goudsmit, P Schellekens, F Barin, D Zagury, M De Wilde, C Bruck.   

Abstract

A direct enzyme immunoassay (EIA) using the recombinant soluble form of CD4 (sCD4) produced in rodent cells as antigen was applied to detect antibodies to CD4 in sera from HIV-1- and HIV-2-infected patients. High titers of antibodies to sCD4 were found in sera from 12.6% of the HIV-1-infected persons included in this study, but not in 120 normal human sera. The reactivity of these antibodies with sCD4 was confirmed by a Western blot analysis. A possible anti-idiotypic origin of those antibodies was thought to be unlikely in view of the lack of inhibition of the binding of the biotin-labeled monoclonal antibody (mAb) anti-Leu3a by sCD4 positive sera. Attempts to correlate the evolution of the disease with the presence or absence of antibodies to sCD4 in a panel of well documented HIV-1-seropositive cases did not reveal any clear correlation. Sera from HIV-2-infected people (nine sera analysed), sera from HIV-1-infected chimpanzees (10 sera analysed) and sera from humans immunized with a recombinant vaccinia virus expressing gp160 (10 sera analysed) scored negative for antibodies to sCD4. The possible origin and biological significance of the observed antibodies to sCD4 are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146262     DOI: 10.1097/00002030-198810000-00003

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

Review 1.  Molecular immunopathogenesis of HIV infection.

Authors:  T T Ng; A J Pinching; C Guntermann; W J Morrow
Journal:  Genitourin Med       Date:  1996-12

2.  Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Authors:  P Yeh; D Landais; M Lemaître; I Maury; J Y Crenne; J Becquart; A Murry-Brelier; F Boucher; G Montay; R Fleer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

3.  An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques.

Authors:  Jennifer A Schwartz; Ilia Prado; Johnathan Misamore; Deborah Weiss; Jesse Francis; Ranajit Pal; Maria Huaman; Anthony Cristillo; George K Lewis; Robert C Gallo; Anthony L DeVico; Timothy R Fouts
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

4.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

5.  Relationship of antibodies against CD4+ T cells in HIV-infected patients to markers of activation and progression: autoantibodies are closely associated with CD4 cell depletion.

Authors:  C Müller; S Kukel; R Bauer
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

Review 6.  HIV-mediated B-lymphocyte activation and lymphomagenesis.

Authors:  J G Monroe; L E Silberstein
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

Review 7.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

8.  Differential isotype expression and binding properties of T cell-reactive antibodies in human immunodeficiency virus (HIV) infection.

Authors:  F Silvestris; C Azzolini; F Dammacco
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

Review 9.  Markers predicting progression of human immunodeficiency virus-related disease.

Authors:  C M Tsoukas; N F Bernard
Journal:  Clin Microbiol Rev       Date:  1994-01       Impact factor: 26.132

10.  Internal-image anti-idiotype HIV-1gp120 antibody in human immunodeficiency virus 1 (HIV-1)-seropositive individuals with thrombocytopenia.

Authors:  S Karpatkin; M A Nardi; Y H Kouri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.